Search
IRPHI PLUS 300 MG / 12.5 MG , Comprimé pelliculé
Details
| --- | Description |
|---|---|
| Pack | Boite de 20 |
| Strength (Dosage) | 300 MG | 12.5 MG |
| Laboratory | PHI |
| Ingredients | Irbesartan | Hydrchlorothiazide |
| Therapeutic class | Antihypertenseur : Association de diurétique et de Antagoniste sélectif des récepteurs de l'angiotensine II |
| ATC code | C09DA04 |
| PPH | $6.86 |
| PPV | $10.97 |
| Refundable | Yes |
| Refund base | $10.97 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Medication |
| Uses | Traitement de l'hypertension artérielle essentielle lorsque l'effet d'une monothérapie reste insuffisant. Traitement initial en cas d'hypertension prononcée, lorsqu'un contrôle rapide de la pression artérielle (en termes de jours ou de semaines) est de première importance clinique. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications with one or more of the ingredients above
Medications under one or more of the therapeutic classes above
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem